Neuroscience Focus Areas:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      +30 YEARS' GLOBAL EXPERIENCE ACROSS MULTIPLE INDICATIONS1-4

       

      CHRONIC MIGRAINE

      BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5

      UK-BCM-240035. DOP: April 2024.

      Chronic migraine: a long and frustrating patient journey6†

      Diagnosing and managing chronic migraine

      Could your patients with chronic migraine benefit from treatment with BOTOX®?

      A real-life patient treatment journey

      Kayte was diagnosed with chronic migraine at 24, and experienced issues with certain treatments before finding one that suited her.

      Learn about her individual experience in this video, and find out about her experience with BOTOX® >

      Initiating a patient on BOTOX®

      How should you consult your patients who are starting on BOTOX®, and how can you ensure treatment adherence?

      Neurologist Dr Andrew Blumenfeld explains in this 6-minute video >

      CM: chronic migraine; CV: cardiovascular; ICHD: International Classification of Headache Disorders.

       

      References

      1. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      2. Allergan. Data on file. INT/0423/2016
      3. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      4. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/859/smpc. Accessed March 2024
      6. Davies P T G, Lane R J M et al. The long and winding road: the journey taken by headache sufferers in search of help. Prim Health Care Res Dev. 2019;20:e4
      7. Natoli J L, Manack A et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609
      8. National Institute for Health and Care Excellence (NICE). CG150: Headaches in over 12s: diagnosis and management. Available at: www.nice.org.uk. Accessed March 2024
      9. Schwedt T J. Chronic migraine. BMJ 2014;348:g1416
      10. National Institute of Health and Care Excellence (NICE) clinical knowledge summary (CKS). Migraine. Available at: https://cks.nice.org.uk. Accessed March 2024
      11. Buse D C, Manack A N et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456-1470
      12. Loder E, Rizzoli P. Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache. 2018;58(Suppl 3):218-229
      13. Woolley J M, Bonafede M M et al. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017;57(9):1399-1408
      14. Blumenfeld A M, Silberstein S D et al. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes. Headache. 2017;57(5):766-777

       

      References

      1. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      2. Allergan. Data on file. INT/0423/2016
      3. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      4. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      5. BOTOX® Summary of Product Characteristics. Available from: https://www.medicines.org.uk /emc/product/859/smpc. Accessed March 2024
      6. Davies P T G, Lane R J M et al. The long and winding road: the journey taken by headache sufferers in search of help. Prim Health Care Res Dev. 2019;20:e4
      7. Natoli J L, Manack A et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609
      8. National Institute for Health and Care Excellence (NICE). CG150: Headaches in over 12s: diagnosis and management. Available at: www.nice.org.uk. Accessed March 2024
      9. Schwedt T J. Chronic migraine. BMJ 2014;348:g1416
      10. National Institute of Health and Care Excellence (NICE) clinical knowledge summary (CKS). Migraine. Available at: https://cks.nice.org.uk. Accessed March 2024
      11. Buse D C, Manack A N et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456-1470
      12. Loder E, Rizzoli P. Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache. 2018;58(Suppl 3):218-229
      13. Woolley J M, Bonafede M M et al. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017;57(9):1399-1408
      14. Blumenfeld A M, Silberstein S D et al. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes. Headache. 2017;57(5):766-777

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      BOTOX® PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected] 

       

      Date of preparation: March 2024. UK-BCM-240047.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.